PH Domain-Only Protein PHLDA3 Is a p53-Regulated Repressor of Akt  by Kawase, Tatsuya et al.
PH Domain-Only Protein PHLDA3
Is a p53-Regulated Repressor of Akt
Tatsuya Kawase,1,8,9,11 Rieko Ohki,1,9,11,* Tatsuhiro Shibata,2,3 Shuichi Tsutsumi,7 Naoko Kamimura,7 Johji Inazawa,6
Tsutomu Ohta,4 Hitoshi Ichikawa,5 Hiroyuki Aburatani,7 Fumio Tashiro,8 and Yoichi Taya1,9,10
1Radiobiology Division
2Cancer Genomics Project
3Pathology Division
4Center for Medical Genomics
5Cancer Transcriptome Project
National Cancer Center Research Institute, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan
6Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku,
Tokyo 113-8510, Japan
7Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro-ku,
Tokyo 153-8904, Japan
8Department of Biological Science and Technology, Faculty of Industrial Science and Technology, Tokyo University of Science,
Yamazaki 2641, Noda-shi, Chiba 270-8510, Japan
9SORST/JST, Kawaguchi Center Building, 4-1-8 Honcho, Kawaguchi-shi, Saitama 332-0012, Japan
10Cancer Research Center of Excellence, Center for Life Sciences, #02-07, 28 Medical Drive, National University of Singapore,
Singapore 117456
11These authors contributed equally to the work
*Correspondence: rohki@ncc.go.jp
DOI 10.1016/j.cell.2008.12.002SUMMARY
p53 and Akt are critical players regulating tumorigen-
esis with opposite effects: whereas p53 transacti-
vates target genes to exert its function as a tumor
suppressor, Akt phosphorylates its substrates and
transduces downstream survival signals. In addition,
p53 and Akt negatively regulate each other to
balance survival and death signals within a cell. We
now identify PHLDA3 as a p53 target gene that
encodes a PH domain-only protein. We find that
PHLDA3 competes with the PH domain of Akt for
binding of membrane lipids, thereby inhibiting Akt
translocation to the cellular membrane and activa-
tion. Ablation of endogenous PHLDA3 results in
enhanced Akt activity and decrease of p53-depen-
dent apoptosis. We also demonstrate the suppres-
sion of anchorage-independent cell growth by
PHLDA3. Loss of the PHLDA3 genomic locus was
frequently observed in primary lung cancers, sug-
gesting a role of PHLDA3 in tumor suppression. Our
results reveal a new mode of coordination between
the p53 and Akt pathways.
INTRODUCTION
Proper regulation of cell death, survival, and proliferation is
fundamental to ensuring homeostasis of a multicellular
organism. Complex signal transduction pathways controlled byoncoproteins and tumor suppressor proteins enable an elabo-
rate balance of growth-promoting and growth-suppressing
signals within a cell. One example of such a pathway is mutual
regulatory crosstalk between tumor suppressor protein p53
and oncoprotein Akt, two key molecules regulating the life and
death of a cell (Cully et al., 2006; Oren, 2003; Vousden and
Prives, 2005).
The Akt signaling pathway plays a central role in cell survival
and proliferation. Several components of this pathway are dysre-
gulated in awide spectrum of human cancers (i.e., Akt, PI3K, and
PTEN), establishing its importance in oncogenesis (Luo et al.,
2003). Mitogenic signals by receptor tyrosine kinases are first
transmitted to phosphatidylinositol 3-kinase (PI3K), leading to
production of a second messenger, phosphatidylinositol (3,4,5)-
trisphosphate (PIP3). PIP3 generation on the inner side of the
plasma membrane leads to translocation and activation of Akt.
Akt activation is regulated by a dual mechanism that requires
both translocation to the plasma membrane and phosphoryla-
tion at Thr308 and Ser473. Akt is recruited to the plasma
membrane through direct interaction with its pleckstrin
homology (PH) domain, functioning as lipid-binding modules.
Downstream of Akt, Akt substrates contribute to the effects of
Akt in cell survival and proliferation (Manning and Cantley, 2007).
In contrast, p53 plays a major role in the induction of growth
arrest and cell death (Harris and Levine, 2005; Liu and Chen,
2006; Oda et al., 2000; Ohki et al., 2000). As the inactivation of
p53 abrogates p53-mediated growth constraints, loss of func-
tional p53 is a prerequisite for oncogenesis and is the most
common anomaly in human cancers (Vogelstein et al., 2000;
Vousden and Prives, 2005). Various stress signals stabilize and
activate p53, which exerts its tumor-suppressive function mainlyCell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc. 535
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Figure 1. PHLDA3 Is Induced by p53
(A–C) PHLDA3 expression was analyzed by northern blotting. Methylene blue staining of 28S ribosomal RNA was also shown to confirm equal loading of RNA in
each lane.
(A) Temperature-sensitive (ts) WT p53- or ts-TAD-S/A-expressing Saos2 cell lines were tested for PHLDA3 induction ability upon temperature shift to the permis-
sive temperature with or without g-ray irradiation. Cells were subjected to g-ray irradiation 2 hr after temperature shift to 32C. Cells were collected 5 or 14 hr
post-temperature shift. Raw northern blotting data are shown in the top panel, and the relative signal intensities for PHLDA3 expression (normalized by 28S
intensities) were quantified by NIH Image J software and are shown below the panel.
(B) MCF7, A549, and MRC5 cells were treated with adriamycin for 18 hr. MM468 cells were transduced with control LacZ-expressing (Ad-LacZ) or p53-express-
ing adenovirus (Ad-p53) at multiplicity of infection (moi) 15 and harvested 18 hr post-infection.
(C) MRC5 cells transduced with control lentivirus or lentivirus expressing p53 shRNA were subjected to g-ray irradiation.
(D) HCT116 p53+/+ and HCT116 p53/ cells were subjected to g-ray irradiation or 5-FU. Cells were harvested at the indicated times following treatment. RNA
was purified from each sample and analyzed by quantitative real-time PCR. The mRNA levels of PHLDA3 and p21 were standardized by mRNA levels of GAPDH.
All samples were run in triplicate, and data are represented as the mean fold expression ± standard deviation (SD).536 Cell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc.
as a transcriptional activator. Many p53 target genes have been
identified that regulate various processes involved in the preven-
tion of tumorigenesis, such as the induction of cell-cycle arrest,
cell death, DNA repair, and senescence. It has been postulated
that target genes are selectively activated to implement different
p53-mediated responses, depending on the stress signal that
activates p53. Posttranslational modification of p53 is the candi-
date mechanism that makes p53 respond to different stress
signals, and phosphorylation of p53 is a major posttranslational
modification of p53 (Bode and Dong, 2004). Moreover, recent
studies have shown the importance of p53 phosphorylation in
the induction of several p53 target genes.
Akt-p53 mutual regulation involves Akt substrates and p53
target genes; for example, one target gene of p53, PTEN, nega-
tively regulates Akt (Mayo and Donner, 2002). PTEN encodes
a phosphatase that dephosphorylates lipid PIP3, which is essen-
tial for Akt activation. On the other hand, p53 is also negatively
regulated by Akt. Akt phosphorylates Mdm2, a negative regu-
lator of p53 that targets p53 for degradation, and Mdm2 phos-
phorylation leads to accelerated degradation of p53. Moreover,
the mdm2 gene is transcriptionally regulated by p53, forming
a p53-Mdm2 autoregulatory feedback loop (Brooks and Gu,
2006). Thus, Akt and p53 negatively regulate each other by a
complex protein network to ensure coordinated growth control
within a cell.
As is evident from the findings of PTEN and Mdm2, identifica-
tion of p53 target genes led to the discovery of tumor-associated
genes. PTEN is a tumor suppressor gene mutated in breast
cancers and gliomas, while mdm2 is an oncogene frequently
amplified in tumors without p53 mutations (Mayo and Donner,
2002). In order to identify genes participating in the regulation
of tumorigenesis, and to dissect the functional relevance of
p53 phosphorylation in target gene induction, we performed
exhaustive analysis to identify p53 target genes that are induced
in a manner dependent on p53 phosphorylation status (Ohki
et al., 2007; Kawase et al., 2008). We found that approximately
80% of genes depended on p53 phosphorylation, showing its
importance in transcriptional activity of p53. Adding to the list
of previously identified genes, we report here a p53 target
gene, PHLDA3, that encodes a PH domain-only protein that
suppresses Akt activity by directly interfering with Akt binding
to membrane lipids. PHLDA3 also inhibits anchorage-indepen-
dent growth and is a candidate tumor suppressor of lung endo-
crine tumors.
RESULTS
PHLDA3 Is a Direct Target Gene of p53
Previously, we identified by microarray expression analysis
genes induced by wild-type (WT) p53 and TAD-S/A, a phosphor-
ylation-defective p53 mutant carrying point mutations at all Ser
residues within the transactivation domain (TAD) (Ohki et al.,2007). As shown in Figures 1A and S1A (available online),
PHLDA3 was one of the identified genes induced by WT p53
but not by TAD-S/A. PHLDA3 transcript was also induced by
exogenous expression of p53, adriamycin treatment in cells
carrying WT p53, g-ray irradiation, and 5-fluorouracil (5-FU) in
a p53-dependent manner (Figures S1B, S1C, and 1B–1D). We
also showed that the induction kinetics of PHLDA3 mRNA was
similar to that of representative target genes of p53 (Figure S1D).
In addition, PHLDA3 protein expression was induced by exoge-
nous expression of p53 and various DNA-damaging agents,
including 5-FU, ultraviolet (UV), and g-ray irradiation, in cell lines
carrying WT p53 (Figures 1E–1G and S2A–S2E). Furthermore,
PHLDA3 and p21 proteins were induced with similar kinetics
by UV and g-ray irradiation (Figures 1G and S2E).
It has been reported previously that the PHLDA3 (also named
Tih1) gene has sequence similarity to an imprinted gene, Ipl
(Frank et al., 1999). As shown in Figure S3, Ipl transcript was
not induced with a dependence on p53, and although PHLDA3
and Ipl genes share sequence homology, they are regulated in
different ways.
As it had been demonstrated thatPHLDA3 is a p53-responsive
gene, we then explored whether PHLDA3 is also a direct target
gene of p53. The consensus binding motif of p53 is composed
of two copies of 50-RRRCWWGYYY-30 (R: purine, Y: pyrimidine,
W: A or T) (Harris and Levine, 2005). As shown in Figure 2A, we
found a putative p53-responsive element (p53RE) upstream of
the PHLDA3 gene, overlapping the transcription initiation site.
Interestingly, this putative p53RE was highly conserved among
the species. In order to clarify if this putative p53RE is activated
by p53, the upstream region of the PHLDA3 gene was cloned
and assayed for p53 responsiveness. We first analyzed whether
promoters with or without p53RE showed p53 responsiveness
by luciferase reporter promoter assay. As shown in Figure 2B,
p53 responsiveness strictly depended on intact p53RE. Further-
more, double-stranded synthetic oligonucleotide containing
p53RE inserted upstream of the luciferase gene conferred strong
p53 response on the promoter, which was abolished when
p53RE was mutated (Figure 2C). On the other hand, the p53
mutant, V143A, which has no transactivation ability, did not acti-
vate the promoters, confirming thatPHLDA3 promoter activation
depends on p53 transcriptional activity (Figures 2B and 2C).
We next analyzed whether p53 protein binds to the PHLDA3
promoter in vivo. As shown in Figure 2D, binding of WT p53 and
TAD-S/A to the PHLDA3 promoter was analyzed by chromatin
immunoprecipitation (ChIP) assay, and it was strengthened
when both p53s were active. Furthermore, we comprehensively
analyzed p53 binding near the PHLDA3 gene, utilizing ChIP-
chip and ChIP sequence technology. As shown in Figures 2E
and S4A, strong and specific binding of endogenous p53 at
p53RE was detected upon DNA damage. The signal obtained
by ChIP-chip analysis was proportional to the strength of p53
binding, and the signal obtained for the PHLDA3 gene was as(E–G) Western blotting was performed to detect PHLDA3 protein expression. In all cases, PHLDA3 protein migrated as a doublet (see also Figure S2A). Expres-
sion and activation (Ser15 phosphorylation) of p53 and expressions of representative p53 target genes (p21 and Noxa) were also analyzed.
(E) MM468 cells were transduced with Ad-LacZ or Ad-p53 at moi 15 and harvested 18 hr post-infection.
(F) Indicated cells were treated with 5-FU for 20 hr. Note that neither PHLDA3 nor p21 protein is induced in cell lines carrying mutant p53.
(G) U2OS cells were treated with UV or g-ray irradiation.Cell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc. 537
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strong as other representative p53 target genes (Figure S4B). In
addition, quantitative PCR was performed to analyze p53RE
enrichment by ChIP. The relative enrichment of PHLDA3 p53RE
after ChIP was compared to a locus with no p53 binding and
was concentrated more than 50-fold (Figure S4C). Moreover,
ChIP sequence assay was performed for histone H3 trimethy-
lated at Lys 4 (trimethyl K4/H3). It has been reported that trimethyl
K4/H3 peaks in the 50 transcribed region and active genes can be
discriminated from inactive genes by high levels of trimethyl K4/
H3 (Schneider et al., 2004). Upon DNA damage, the PHLDA3
gene was actively transcribed and increased trimethyl K4/H3
was detected in the 50 transcribed region simultaneously (Figures
S1D and 2E). We finally analyzed, by p53 pull-down assay using
biotinylated DNA probes containing one or two copies of p53RE,
whether p53 binds directly to p53RE. As shown in Figure 2F, p53
was pulled down by WT but not by mutant p53RE. Collectively,
these results identify PHLDA3 as a bona fide target gene of p53
and p53RE as the p53-responsive element of the PHLDA3 gene.
PHLDA3 Expression Is Regulated by p53
Phosphorylation Status
Multiple phosphorylation occurs within the TAD of p53 and regu-
lates p53 transcriptional activity (Bode and Dong, 2004). As
shown in Figures 1A and 2G, we found that PHLDA3 expression
and promoter activation was severely diminished in cells ex-
pressing TAD-S/A. We therefore analyzed which Ser residue
within the TAD contributes to PHLDA3 expression. We con-
structed p53 phosphorylation-deficient mutants carrying single
amino acid conversions from Ser to Ala on all Ser residues within
the TAD. As shown in Figure 2G, while p53 Ala mutants at Ser6,9, 20, 33, and 37 showed activity similar toWT p53, themutant at
Ser15 showed decreased activity, similar to TAD-S/A. In addi-
tion, phosphorylation-mimic mutant S15D showed enhanced
promoter response (Figure 2G, right panel). The requirements
for Ser15 phosphorylation were also confirmed by analyzing
endogenous PHLDA3 transcriptional activation by WT p53,
TAD-S/A, S15A, S15D, or S46A (Figure 2H) and by mutants
carrying combined (S15, 20A and S6, 33, 46A) amino acid
conversions (Figure S5A). On the other hand, although weak
impairment of PHLDA3 promoter activation was observed for
S46A (Figure 2G left panel), it was not observed for endogenous
PHLDA3 induction (Figures 2H and S5A).
Phosphorylation of Ser15 upon genotoxic stress is dependent
on ATM (Bode and Dong, 2004). Upon g-ray irradiation, efficient
Ser15 phosphorylation and PHLDA3 expression were detected,
whereas both were diminished in the same cells treated with
caffeine, an ATM inhibitor (Figure 2I). Furthermore, when cells
were treated with siRNA targeting ATM, Ser15 phosphorylation
and PHLDA3 expression reduced simultaneously upon g-ray
irradiation (Figure 2J). We also analyzed PHLDA3 expression
in ATM-proficient normal human fibroblast WI-38 and ATM-defi-
cient AT2KYfibroblasts and showed that ATM is required for both
Ser15 phosphorylation and PHLDA3 expression (Figures S5B
and S5C). These results collectively support the idea that p53
activation uponDNAdamage is regulated bySer15 phosphoryla-
tion, and PHLDA3 expression is dependent on it. ChIP analysis
results showed that TAD-S/A can bind to the PHLDA3 promoter
as efficiently asWT p53 (Figure 2D); however, TAD-S/A is unable
to fully activate the PHLDA3 promoter. The phosphorylation
status of p53may not affect p53 binding to thePHLDA3promoterFigure 2. PHLDA3 Is a Direct Target Gene of p53
(A) Genomic organization of PHLDA3 (chr1: 198, 164, 473–198, 171, 696) is shown together with the plots of pairwise genomic alignments between human and
mouse, human and rat, and human and chicken. Genomic alignment plots were constructed using VISTA (http://genome.lbl.gov/vista/index.shtml). Based on
genomic alignments, nucleotide conservation was calculated with a 100 bpwindow, and conservation percentage is shown as a plot. The position and nucleotide
sequence of p53-responsive element are shown at the bottom.
(B) PHLDA3 promoter region with or without p53RE (shown as an oval) was cloned upstream of firefly luciferase reporter gene with a minimal promoter, and lucif-
erase reporter assay was performed. Constructs contain indicated positions relative to the transcription initiation site. Nucleotides that matched p53 consensus
binding sites, 4th and 7th nucleotides for promoter 2mut.1 and 14th nucleotide for promoter 2mut.2, weremutated. Constructs were tested for transactivation by
WT p53 and p53-V143A. The assay was performed 24 hr post-transfection. The experiment was run in triplicate, and data are represented as the mean fold acti-
vation ± SD.
(C) One or two copies of double-stranded synthetic oligonucleotide containing p53RE were inserted into the luciferase repoter plasmid containing a minimal
promoter. The assay was performed as in (B).
(D) ChIP assay was performed for the PHLDA3 promoter. The ts WT p53- and TAD-S/A-expressing Saos2 cell lines were used to analyze p53 binding to the
PHLDA3 promoter upon temperature shift to the permissive temperature. The positions of PCR primers within the PHLDA3 promoter region are shown at the top.
(E) HCT116 p53+/+ cells were treated with 5-FU, and p53 ChIP-chip or trimethyl K4/H3 ChIP sequence analysis was performed. Genomic locus of PHLDA3 is
shown together with the results obtained. Vertical axis shows the probability value (-log P), which reflects the fold enrichment of ChIP-chip or ChIP sequence
samples. Blue and red lines at the top indicate the p53-consensus region computed from TRANSFAC analysis. One p53-consensus region matched completely
with p53RE obtained from our analysis (shown by a red line).
(F) p53 pull-down using biotinylated DNA probes was performed. Two additional DNA probes served as controls: one containing the p21-derived sequence (p21-
p53RE) as a positive control and another containing a nonrelevant sequence derived from a plasmid as a negative control. Bound p53 was analyzed by western
blotting.
(G–J) Full activation of the PHLDA3 promoter requires p53 phosphorylation, especially at Ser15.
(G) Luciferase assay was performed as in (B) using promoter 2. Saos2 cells were transfected with the indicated constructs and promoter 2 and analyzed 48 hr
post-transfection.
(H) Endogenous PHLDA3 expression was analyzed by northern blotting. Saos2 cells were transfected with the indicated p53s and harvested 24 hr post-trans-
fection. Relative signal intensities for PHLDA3 expression were quantified as in Figure 1A and are shown below the panel. p53 protein levels were analyzed and
are shown in the bottom panel. Asterisk denotes a nonspecific band detected by anti-p53 polyclonal antibody.
(I) MCF7 cells were subjected to g-ray irradiation with or without caffeine. Caffeine was added to the medium 1 hr prior to g-ray irradiation. Cells were harvested
4 hr post-irradiation. Western blotting was performed to detect p53 expression and activation (Ser15 phosphorylation of p53).
(J) MCF7 cells were transfected with siRNA targeting ATM and analyzed as in (I).Cell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc. 539
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Figure 3. PHLDA3 Induces Apoptosis and Represses Akt
(A) PHLDA3 induces caspase-dependent cell death. MM468 cells were transduced with Ad-LacZ or N-terminally HA-tagged PHLDA3-expressing adenovirus
(Ad-PHLDA3) at moi 15. Cells were cultured with or without caspase-specific peptide inhibitor z-VAD-fmk. Cells were harvested 48 hr post-infection and analyzed
by FACS. Percentages of cells with sub-G1 DNA content are shown (bottom panel).540 Cell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc.
but may affect other aspects of PHLDA3 promoter activation,
such as cofactor recruitment to the promoters, leading to its
efficient activation.
PHLDA3 Is an Apoptosis Inducer
To explore the physiological functions of PHLDA3, we first trans-
duced PHLDA3 by adenovirus-mediated gene transfer and
analyzed the effect of ectopic PHLDA3 expression. As shown
in Figures S6A and S9B, PHLDA3 induced cell death in several
cell lines irrespective of the p53 status, consistent with PHLDA3
as a downstream mediator of p53. We found that cells with
sub-G1 DNA content were increased by PHLDA3 expression
(Figure S6A), and this increase was inhibited by z-VAD-fmk addi-
tion, a specific caspase inhibitor, showing that PHLDA3-induced
cell death is caspase dependent (Figure 3A). In addition, cas-
pase 3 activation and increased annexin V-positive/PI-negative
cells were observed upon PHLDA3 expression (Figures 3B and
S6B). We also compared the cell death-inducing ability of
PHLDA3 with that of p53 and Noxa, a representative p53 target
gene that induces apoptosis (Figure S6C). Although cell-death
induction was weaker than that with p53, PHLDA3 induced cell
death similarly to Noxa. Besides, we showed that endogenous
PHLDA3 is required for p53-dependent apoptosis (Figure 5, dis-
cussed in detail later). Collectively, it was shown that PHLDA3
expression leads to apoptosis induction.
PHLDA3 Induces Apoptosis through Its PH Domain
PHLDA3 protein is highly conserved in vertebrates and is a small
protein of 127 aamostly comprised of the PHdomain (Figure S7).
Based on the results of the in vitro phosphatidylinositol phos-
phate (PIP) binding assay, thePHdomain of PHLDA3 is functional
and binds to most PIP (Figure 3C and Saxena et al., 2002).
PHLDA3 binding to PIP occurs without stimulation and therefore
PHLDA3 is localized to the cellular membrane when expressed
(Figure S8). Accordingly, we tested whether PHLDA3’s ability to
induce apoptosis is dependent on the function of its PH domain.
We fusedWT PHLDA3 (WT PHLDA3) andmtPHLDA3, a PHLDA3
mutant with a small deletion within the PH domain (Figure S7),
with GFP or DsRed, and subcellular localization was analyzed.
As shown in Figures 4C and 4D, while DsRed-WT PHLDA3 local-ized to the plasma membrane as expected, DsRed-mtPHLDA3
localized mainly in the cytoplasm, showing that the PH domain
of mtPHLDA3 is nonfunctional (equivalent GFP fusion proteins
showed the same subcellular localizations, Figure 3F and data
not shown). We next expressed GFP, GFP-WT PHLDA3, and
GFP-mtPHLDA3 in 293T cells and analyzed GFP-positive cells
by flow cytometry. As shown in Figure 3D, compared to GFP-
expressing cells, an increase of dead cells was observed in cells
expressing GFP-WT PHLDA3, while no increase was observed
for cells expressing GFP-mtPHLDA3. These results demonstrate
that the functional PH domain is required for PHLDA3-induced
apoptosis.
PHLDA3 Acts Similarly to the PH Domain of Akt
The PH domain is an approximately 100-residue protein module
found in many signaling proteins and binds to PIP located on the
inner plasma membrane. The PH domain mediates protein
recruitment to cellular membranes, which is of paramount impor-
tance for signal transduction (Lemmon and Ferguson, 2000).
Given that apoptosis induction of PHLDA3 requires its PH
domain, and PHLDA3 has no distinct functional domain other
than the PH domain, we speculated that the physiological role
of PHLDA3 is to function as a PH domain-only protein. We
hypothesized that PHLDA3 is induced by p53 under stressed
conditions, functioning as a dominant-negative molecule for
other PH domain-containing proteins to shut off the signal trans-
duction pathway mediated by those proteins. In order to test our
hypothesis, we tested whether PH domains derived from other
PH domain-containing proteins function similarly to PHLDA3
within the cell. We selected two well-known PH domain-contain-
ing proteins with distinct functions within the cell: serine/
threonine kinase Akt, the main molecule that transduces survival
signaling, and Grp1, a member of the GTP-binding protein
exchange factor family that regulates cell adhesion and
spreading (Lemmon and Ferguson, 2000). It has been reported
that bothPHdomains of Akt andGrp1bind toPIP3, andwhen iso-
lated PH domains are expressed in cells, they function as domi-
nant-negative formsof theproteins (Songyanget al., 1997; Varnai
et al., 2005). The PH domain of Akt or Grp1 was fused with GFP
(GFP-PH-Akt, GFP-PH-Grp1) and expressed in 293T and COS7(B) Cleavage and activation of caspase 3 upon PHLDA3 expression. MM468 and WI-38 cells were transduced with Ad-LacZ, Ad-PHLDA3, or Ad-p53 at moi 35.
Cells were harvested at the indicated times post-infection. HeLa cells treatedwith staurosporine for 6 hr were shown as a positive control for caspase 3 activation.
PHLDA3 expression was detected with anti-HA antibody. Caspase 3 activation induced by PHLDA3 followed that by p53.
(C) Binding of GST-PHLDA3, GST-PH-Akt, or GST to immobilized PIP was assessed by protein-lipid overlay assay. Nitrocellulose membranes spotted with 100
pmol of different phospholipids were used for the assay. Bound proteins were detected with anti-GST antibody. Note that GST produced no signal under the
conditions employed.
(D) 293T cells were transfected with GFP, GFP-WT PHLDA3, GFP-mtPHLDA3, GFP-PH-Akt, or GFP-PH-Grp1 and analyzed for GFP-positive cells 48 hr post-
transfection. The apoptotic rate, measured by PI-positive cells (cells stainedwith PI without fixation), is shown.Mean apoptotic rates ±SD from three experiments
are shown.
(E) PHLDA3 inhibits Akt activation. COS7 cells were transfectedwith the indicated fusion proteins for 24 hr and subsequently stimulatedwith EGF for 5min. Induc-
tion of Akt phosphorylation was detected in control cells expressing GFP upon EGF treatment. Akt activity after EGF treatment was analyzed by western blotting,
and Akt activity relative to the GFP-transfected control was calculated. The mean ± SD from three experiments is shown. GFP fusion protein levels were also
analyzed by western blotting.
(F) Cell spreading is not inhibited by PHLDA3. The cell-spreading assay was performed. LY294002 was added 10min before re-plating. More than 150 cells were
counted from three fields, and the percentages of fully spread cells are shown. Note that PI3K inhibitor LY294002 inhibited cell spreading under the conditions
tested. Mean percentage ± SD from three fields is shown. Representative images of cells are shown on the left.
(G) Cell attachment is only weakly inhibited by PHLDA3. Cell attachment assay was performed. Attached cells were harvested and analyzed by western blotting.
The fraction of attached cells relative to input cells was calculated for each construct. LY294002 (added 10min before plating) inhibited cell attachment under the
conditions tested. Representative result is shown on the left, and the mean ± SD from four experiments is shown.Cell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc. 541
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Figure 4. PHLDA3 Interferes with Akt Activation by Inhibiting Akt Binding to PI(3,4)P2 and PI(3,4,5)P3
(A) Indicated cells were infected with Ad-LacZ, Ad-p53, or Ad-PHLDA3 at moi 35 and analyzed 18 hr post-infection, when apoptotic cells were not yet detected.
Akt and Erk activities were assessed by analyzing phosphorylated Akt and Erk1/2 by western blotting.
(B) Constitutively active Akt represses apoptosis induced by PHLDA3. MM468 cells stably expressing myr-Akt or control cells expressing only the Bsr drug resis-
tance gene were infected with Ad-LacZ or Ad-PHLDA3 at moi 15. Myr-Akt was detected with anti-Akt antibody. Cells were fixed and stained with Giemsa 48 hr
post-infection (left lower panel). Cells in sub-G1 were also analyzed by FACS (right panel). The data are represented as the mean ± SD for triplicate samples.542 Cell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc.
cells. As expected, GFP-PH-Akt repressed Akt activity and
induced apoptosis by inhibition of the Akt pathway (Figures 3D
and 3E), whereasGFP-PH-Grp1 inhibited cell spreading on fibro-
nectin and cell attachment to culture dishes by inhibiting endog-
enous Grp1 signaling (Figures 3F and 3G). GFP-PH-Akt had no
effect on cell spreading and a veryweak effect on cell attachment
(Figures 3F and3G), andGFP-PH-Grp1 had a veryweak effect on
cell survival and no effect on Akt activity (Figures 3D and 3E),
showing the selective effect of these PH domains, as reported
(Varnai et al., 2005). We found that GFP-WT PHLDA3 induced
apoptosis and repressed Akt activity as GFP-PH-Akt, whereas
it had a very weak effect on cell spreading and attachment,
showing that PHLDA3 functions similarly to the PH domain of
Akt (Figures 3D–3G).
PHLDA3 Induces Apoptosis by Inhibiting Akt Activity
PHLDA3 represses Akt activity and induces apoptosis, suggest-
ing that it functions as a PH domain-only protein to inhibit Akt;
therefore, we further examined whether PHLDA3 induces
apoptosis by inhibiting Akt activation. As shown in Figure 4A,
PHLDA3 expression resulted in diminished Akt phosphorylation
at Ser473 and Thr308, both of which are essential for Akt activity,
whereas the phosphorylation status of Erk was not changed by
PHLDA3 expression, showing that inhibition of Akt activity is
not a result of inhibition of the global cell survival signaling
pathway. We also compared sensitivity to apoptosis induction
by LY294002, a specific PI3K/Akt signaling pathway inhibitor,
and apoptosis by PHLDA3 expression within several cell lines
(Figures S9A and S9B). Cell lines sensitive to LY294002 treat-
ment were also sensitive to PHLDA3 expression. Furthermore,
when MM468 cells were treated with LY294002, PHLDA3
expression did not enhance apoptosis, indicating that PHLDA3
expression does not increase PI3K pathway inhibition in
apoptosis induction (Figure S9C). These results collectively
suggest that apoptosis induction by PHLDA3 is mediated by
inhibition of the PI3K/Akt pathway.
We next tested whether the expression of constitutively active
forms of Akt restrains apoptosis induced by PHLDA3. We
selected two constitutively active forms of Akt, neither of which
require PIP3 binding for activation: a double mutant mimicking
phosphorylated Akt (T308D/S473D-Akt) and myristoylated and
PH domain-deleted constitutively active Akt (myr-Akt). We first
transfected 293T cells with GFP-PHLDA3 and T308D/S473D-
Akt. As shown in Figure S10A, by cotransfection of T308D/
S473D-Akt, PHLDA3-induced apoptosis was rescued, and this
rescue was dependent on T308D/S473D-Akt dosage. When
the effect of T308D/S473D-Akt on apoptosis induced by
PHLDA3 andPH-Akt was compared, T308D/S473D-Akt similarlyrescued both (Figure S10B). We next obtained cells stably ex-
pressing myr-Akt and analyzed apoptosis induction by ectopic
PHLDA3 expression. As shown in Figure 4B, compared to
control cells, apoptotic cells decreased and viable cells
increased in myr-Akt-expressing cells, showing that myr-Akt
efficiently repressed apoptosis induced by PHLDA3. Thus, these
results reveal that PHLDA3 inhibits Akt activation, and Akt inhibi-
tion mainly contributes to apoptosis induction by PHLDA3.
PHLDA3 Interferes with Akt Translocation
to the Plasma Membrane
Activation and phosphorylation of Akt require prior PIP binding at
the plasmamembrane (Stokoe et al., 1997).WhenPI(3,4,5)P3 and
PI(3,4)P2 are generated by PI3K upon growth stimulation, Akt
translocates from the cytoplasm to the plasma membrane by
binding to PIP through its PH domain, which specifically binds
to PI(3,4,5)P3 or PI(3,4)P2 (Figure 3C and Scheid and Woodgett,
2003). Since two constitutively active forms of Akt that do not
require PIP binding for activation rescued PHLDA3-induced
apoptosis, it was suggested that PHLDA3 inhibits Akt binding to
PIP. We therefore analyzed whether PHLDA3 expression inhibits
Akt translocation to the plasmamembraneuponPIP3 production.
We coexpressed DsRed or DsRed-WT PHLDA3 together with
GFP-PH-Akt inNIH3T3cells (Figures 4CandS11A).GFP-PH-Akt
has been shown to mimic Akt translocation upon PI3K pathway
activation (Harriague and Bismuth, 2002). As has been reported,
PDGF treatment of control cells expressing DsRed resulted in
GFP-PH-Akt translocation to the plasma membrane, whereas in
cells expressing DsRed-WT PHLDA3, GFP-PH-Akt translocation
was inhibited. Moreover, inhibition was not observed in cells ex-
pressing DsRed-mtPHLDA3, a PHLDA3 mutant with a defective
PH domain, which cannot localize at the plasma membrane. To
assess the effect of PHLDA3 expression on Akt localization in
other cell lines, a similar experiment was performed using 293T
cells with constitutively active PI3K activity. Again in 293T cells,
DsRed-WT PHLDA3 interfered with GFP-PH-Akt localization to
the plasma membrane, while DsRed or DsRed-mtPHLDA3 did
not (Figures 4D and S11B). Taken together, the results show
that PHLDA3 impedesAkt translocation to the cellularmembrane
and subsequent activation in a manner dependent on its PH
domain function.
PHLDA3 Directly Interferes with Akt Binding
to PIP2 and PIP3
Because PHLDA3 expression led to the inhibition of Akt translo-
cation to the plasma membrane and subsequent phosphoryla-
tion and activation, we next analyzed the mechanism by which
PHLDA3 inactivates Akt. We first tested whether PHLDA3(C) Akt translocation to the plasmamembrane upon PDGF treatment was analyzed by live-cell imaging. NIH 3T3 cells were transfected with GFP-PH-Akt together
with DsRed, DsRed-WT PHLDA3, or DsRed-mtPHLDA3. GFP-PH-Akt subcellular localization wasmonitored before and after PDGF treatment (15min). Note that
Akt is localized at the plasma membrane in cells expressing DsRed or DsRed-mtPHLDA3 (shown by arrows).
(D) Akt subcellular localization in 293T cells with the constitutively active PI3K/Akt pathway. 293T cells were transfected with GFP-PH-Akt together with DsRed,
DsRed-WT PHLDA3, or DsRed-mtPHLDA3, and GFP-PH-Akt subcellular localization was analyzed. Arrows indicate Akt localized at the plasma membrane.
(E) Quantification of PIP3 in cells expressing PHLDA3. Amount of PIP3 was quantified in lipids extracted fromMM468 cells infected with Ad-LacZ and Ad-PHLDA3
and cells treated with LY294002. The data are represented as the mean ± SD from three experiments.
(F) PHLDA3 inhibits PH-Akt binding to PIP2 and PIP3. Binding of GST-PH-Akt to immobilized PIP was assessed by protein-lipid overlay assay. Nitrocellulose
membranes spotted with serially diluted PIP2 and PIP3 were incubated with the indicated proteins. While GST did not interfere with Akt binding to PIP, PHLDA3
significantly interfered. Bound Akt was detected with anti-Akt PH domain antibody.Cell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc. 543
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Figure 5. PHLDA3 Is Required for p53-Dependent Apoptosis
(A and B) Downregulation of PHLDA3 results in decreased p53-dependent apoptosis and elevated Akt phosphorylation. Ctrl-sh, PH3-sh1, and PH3-sh2 cells
were infected with Ad-p53 at moi 3 (in A) or moi 1 (in B). Apoptotic cells as determined by cells with sub-G1 DNA content were analyzed 43 hr post-infection,
and the mean ±SD for triplicate samples is shown (A). In (B), cells were treated with z-VAD-fmk to protect Akt from p53-dependent Akt degradation. Cells
were harvested 50 hr post-infection and analyzed by western blotting.
(C–G) Control or PHLDA3-targeting siRNAs were introduced into LNCaP cells. Cells were treated with adriamycin or 5-FU 30 hr post-transfection. Cells were
harvested 42 hr (C–E and G) or 36 hr (F) post-treatment and analyzed by western blotting (C, D, F, and G) or by FACS for annexin V-positive/PI-negative cells
(E). The mean ± SD for triplicate samples is shown.544 Cell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc.
inhibits Akt activity by affecting upstream signals of Akt. Since
PI3K-produced PIP3 is essential for Akt activation, we analyzed
the amount of PIP3 in cells expressing PHLDA3 using the PIP3
mass strip kit. Acidic lipids were extracted from MM468 cells in-
fected with Ad-LacZ and Ad-PHLDA3 and blotted onto a PIP3
strip. PIP3 was quantified by detecting membrane-blotted acidic
lipids with a PIP3 detector. As shown in Figure 4E, no difference
in the amount of PIP3 was detected between control and
PHLDA3-expressing cells, while significantly reduced PIP3 was
detected in MM468 cells treated with LY294002. As PHLDA3
did not affect Akt upstream signals, we next tested whether
PHLDA3 physically interacts with Akt to inhibit Akt binding to
PIP. HA-tagged Akt and GFP-PHLDA3 or GFP-Akt were coex-
pressed and immunoprecipitated with anti-HA antibody and
analyzed to identify direct interaction between the proteins (Fig-
ure S12). Although Akt homodimerization was detected, as
previously reported (Franke et al., 1997), no interaction between
PHLDA3 and Akt was observed. We finally performed an in vitro
protein-lipid overlay assay to see if PHLDA3 directly interferes
with Akt binding to PIP (Figure 4F). PHLDA3 and Akt were mixed
in a molar ratio of 1:1 and reacted with PI(3,4,5)P3 and PI(3,4)P2
to test whether PHLDA3 competitively interferes with Akt binding
to PIP. As shown in Figure 4F, Akt binding to PIPwas significantly
inhibited by PHLDA3 but not when Akt was mixed with control
GST. Collectively, these results demonstrate that PHLDA3
does not change the amount of PIP3 within the cell or interact
physically with Akt but does repress Akt activity by competitively
binding to PIP.
PHLDA3 Contributes to p53-Dependent Apoptosis
and Repression of Akt
We next examined whether PHLDA3 contributes to p53-
depedent apoptosis. We stably knocked down PHLDA3 in
MM468 cells by introducing two different shRNAs (PH3-sh1
and PH3-sh2) that efficiently knocked down PHLDA3 expression
(Figures S1C, S2B, andS14B). As shown in Figure S2B, induction
of p21 or Noxa by p53-expressing adenovirus (Ad-p53) did not
differ among ctrl-sh, PH3-sh1, and PH3-sh2 cells, showing that
the p53 pathway is normal except for PHLDA3 induction in
PH3-sh1 and PH3-sh2 cells. Using these cell lines, the efficacy
of p53-dependent apoptosis induced by Ad-p53 infection
was analyzed. Apoptosis was not observed in cells infected
with control LacZ-expressing adenovirus (Ad-LacZ), whereas
Ad-p53 induced apoptosis in ctrl-sh cells; however, apoptosis
by Ad-p53 was significantly diminished in PH3-sh1 and 2 cells
(Figure 5A).
Inhibition of the survival signaling pathway by Akt is important
for p53-dependent apoptosis (Stambolic et al., 1999), and
repression of Akt activity was observed upon p53 expression
in MM468 cells (Figures 4A and 5B, lane 4). It has been proposed
that p53-dependent inhibition of the Akt pathway is mediated by
PTEN or caspase (Oren, 2003); however, as MM468 cells do not
have functional PTEN and no degradation of Akt is detected, Aktrepression by p53 detected here is independent of caspase and
PTEN. These results suggest a novel Akt-repressing pathway
downstream of p53. We therefore analyzed whether PHLDA3
acts downstream of p53 to repress Akt. As shown in Figure 5B,
in Ad-p53 infected cells, PH3-sh cells showed elevated Akt
phosphorylation compared to ctrl-sh cells, demonstrating the
involvement of PHLDA3 in p53-dependent repression of Akt
(lanes 4–6). All cells infected with Ad-p53 showed lower Akt
phosphorylation levels than equivalent cells infected with
Ad-LacZ, at least partially because of residual PHLDA3 induction
by p53 in PH3-sh cells. Notably, PHLDA3 expression levels had
a reverse correlation with Akt phosphorylation levels. Cells with
high PHLDA3 expression had very low levels of activated Akt
(lane 4), cells with moderate PHLDA3 expression had medium
levels (lanes 1, 5, and 6), and cells with very low PHLDA3 expres-
sion had high levels (lanes 2 and 3).
We further analyzed involvement of PHLDA3 in p53-depen-
dent apoptosis and Akt repression induced by DNA damage.
LNCaP cells were transfected with control or PHLDA3-targeting
siRNAs and treated with adriamycin or 5-FU, which induces
p53-dependent apoptosis (Figure S13). Upon treatment with
the reagents, upregulation of p53 and p21 was observed (Fig-
ures 5C and 5D). PHLDA3 expression was effectively downregu-
lated in cells transfected with siRNAs targeting PHLDA3 and,
upon DNA damage, PARP cleavage and annexin V-positive/
PI-negative cells were reduced, showing that PHLDA3mediated
DNA damage-induced apoptosis (Figures 5C–5E). Moreover,
Akt activity was higher in cells with ablated PHLDA3 expression,
indicating involvement of PHLDA3 in Akt repression upon DNA
damage (Figures 5F and 5G). Taken together, these results
demonstrate that PHLDA3 is required for p53-dependent
apoptosis and Akt repression.
PHLDA3 Represses Akt under Basal Conditions
In addition to the effects of PHLDA3 knockdown upon p53
activation, we analyzed the effects under basal conditions. In
PH3-sh cells infected with Ad-LacZ, elevated Akt phosphoryla-
tion was observed compared to ctrl-sh cells, showing that
p53-independent basal PHLDA3 expression also inhibits Akt
activation (Figure 5B, lane 1–3). Furthermore, as shown in Fig-
ure 5H, when control- and PH3-sh2 cells were transfected with
GFP-PH-Akt, stronger localization of GFP-PH-Akt was observed
in PH3-sh2 cells, further demonstrating the ability of PHLDA3 to
inhibit Akt membrane translocation. In addition, we analyzed
the effect of PHLDA3 knockdown under basal conditions in
LNCaP cells (Figure 5I). It has been reported that Akt phosphory-
lates Mdm2 and increases Mdm2 activity to degrade p53 (Mayo
and Donner, 2002). In PHLDA3 knocked-down cells, Akt and
Mdm2 activities, elucidated by their phosphorylation, were
increased (Figure 5I). Moreover, p53 levels were lower in these
cells than control cells (Figure 5I and lanes 1–2 of Figures 5C
and 5D); however, no such p53 decrease was observed when
cells were treated with DNA-damaging agents, probably due to(H) Ctrl-sh or PH3-sh2 cells were transfectedwithGFP-PH-Akt and treatedwith EGF for 5min 24 hr post-transfection. Representative images of cells are shown in
top panels. More than 150 cells were counted from three fields and classified into three groups: high, middle, or low GFP-PH-Akt at the plasma membrane.
Percentage of cells with high GFP-PH-Akt localization at the membrane is shown in the bottom panel. The mean ± SD from three fields is shown.
(I) Control or PHLDA3-targeting siRNAs were introduced into LNCaP cells. Cells were harvested 72 hr post-transfection and analyzed by western blotting.Cell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc. 545
p53 phosphorylation protecting p53 against degradation by
Mdm2 (lanes 3–6 of Figures 5C and 5D). These data demonstrate
the complexmutual regulation of Akt andp53 and participation of
PHLDA3 in the signaling cascade.
PHLDA3 Inhibits Anchorage-Independent Cell Growth
Since PHLDA3 mediated Akt inhibition without p53 activation,
we further analyzed p53-independent function of PHLDA3. Akt
is known to enhance anchorage-independent cell growth (Moore
et al., 1998). We therefore analyzed whether PHLDA3 expression
affects Akt-dependent colony formation in soft agar using
MM468 cells without functional p53. In order to confirm Akt func-
tion in growth enhancement in soft agar, we first analyzed
whether colony formation is enhanced in MM468 cells express-
ingmyr-Akt. As shown in Figures 6A, 6B, and S14A, compared to
control cells, cells expressing myr-Akt formed larger and more
colonies in soft agar. We then analyzed the effect of PHLDA3
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Figure 6. PHLDA3 Suppresses Anchorage-Inde-
pendent Cell Growth
(A and B) Control and myr-Akt-expressing cells (1 3 104
cells) were plated in soft agar and cultured for 4 weeks.
Colonies were analyzed by Image J software. Colonies
were counted from three plates and the mean numbers
of colonies ± SD are shown (B).
(C–F) Ctrl-sh, PH3-sh1, and PH3-sh2 cells were plated
and analyzed as described above (D and E).
(C and F) PHLDA3 knock-down efficiency and Akt activity
in colonies were analyzed. Whole-cell lysate (WCL) was
prepared from colonies formed in soft agar from indicated
cells and analyzed for PHLDA3 expression (C) and Akt
activity (F) by western blotting.
(G) Novel Akt-inhibiting pathway downstream of p53
mediated by PHLDA3.
knockdown on colony formation efficiency.
PHLDA3 expression under basal conditions or
in cells forming colonies was analyzed and
was almost undetectable in PH3-sh cells (Fig-
ures 6C and S14B). Similar to the results ob-
tained with cells expressing myr-Akt, cells with
ablated PHLDA3 expression formed larger and
more colonies than ctrl-sh cells (Figures 6D,
6E, and S14C). When Akt phosphorylation
levels of cells grown in soft agar were analyzed,
those of PH3-sh cells were higher than those
of control cells (Figure 6F). Taken together,
PHLDA3 inhibited anchorage-independent cell
growth and Akt activity independent of p53,
suggesting a p53-independent role of PHLDA3
in tumor suppression.
The PHLDA3 Gene Is Frequently Lost
in Human Lung Endocrine Tumors
Inhibition of theAkt survival pathway is central to
tumor suppression, and because PHLDA3
represses Akt in both p53-dependent and -inde-
pendent manners, we considered that PHLDA3
might suppress human tumors. It has been
reported that PI3K/Akt pathway activation is highly important
for the oncogenicity of lung tumors (Engelman and Cantley,
2006). Accordingly, we performed comprehensive copy number
analysis of primary human lung tumors (158 cases), 45 adenocar-
cinomas, 12 bronchioalveolar carcinomas, 52 squamous cell
carcinomas, 8 small cell lung carcinomas, 29 LCNECs (large-
cell neuroendocrine carcinoma), and 13 carcinoids, using
a custom-made array spotted with 800 BAC clones (Peng et al.,
2005; Shibata et al., 2005; and T.S., unpublished data). The
PHLDA3 gene is located in region 199.7 M chromosome 1, and
because the most closely mapped BAC to PHLDA3 in the array
is that containing PTPN7, we judged chromosomal copy number
changes ofPHLDA3 by copy number changes of BAC containing
PTPN7 (chromosomal locations of genes, Figure 7A). Interest-
ingly, while no chromosomal alteration at the PTPN7 locus was
observed in adenocarcinoma, bronchioalveolar, squamous cell,
and small-cell lung carcinoma, frequent chromosomal loss was546 Cell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc.
A6
8
10
12 *
0
2
4
A B C D E 1T 2T 3T 4T 5T 7T 8T 9T 10T 11T 12T
Normal Tumor
re
la
tiv
e 
ex
pr
es
si
on
 o
f P
HL
DA
3
D
Chromosome 1q PHLDA3
190 200195185180 205 (M)
D1S2622
D1S306
D1S510
D1S249
PTGS2
PTPN7 PCTK3
KISS1
B
6
8
10
12
p=0.00028
8.03
-2
0
2
4
Normal Tumor
1.88
re
la
tiv
e 
ex
pr
es
si
on
 o
f P
HL
DA
3
0.86 0.88 1.00 1.24 1.26 0.94 0.97 1.19 0.78 1.16 0.87 1.33
0.98 1.02 1.13 1.36 1.49 1.09 1.09 1.54 0.85 1.25 0.92 1.64
1.25 1.46 1.57 1.77 2.06 1.53 1.56 2.17 1.10 1.80 1.25 1.87
1.15 1.41 1.40 1.50 2.12 1.33 1.48 1.64 0.96 1.36 1.15 1.68
0.69 0.61 0.77 0.96 1.05 0.75 0.92 0.93 0.78 0.84 0.79 1.15
0.70 0.63 0.79 1.03 0.98 0.79 0.77 1.21 0.99 0.74 1.06
0.69 0.68 0.83 1.04 1.13 0.79 0.85 0.98 0.92 0.87 1.13
0.83 0.80 0.96 1.14 1.29 0.89 1.14 1.27 0.81 1.00 0.84 1.24
0.80 0.79 0.97 1.18 1.21 0.92 0.97 1.07 0.75 1.03 0.94 1.34
0.96 1.07 1.13 1.29 1.53 1.09 1.16 1.29 0.95 1.20 1.01 1.63
0.80 0.79 0.92 1.19 1.13 0.91 0.92 1.17 0.73 0.95 0.86 1.25
0.93 1.09 0.82 1.30 1.51 1.08 1.39 1.25 0.87 1.19 0.94 1.45
1.11 1.26 1.33 1.57 1.76 1.36 1.39 1.57 0.98 1.48 1.08 1.75
1.04 1.24 1.33 1.49 1.81 1.20 1.59 1.99 0.99 1.30 1.10 1.80
Locus x Sample 1T 2T 3T 4T 5T 6T 7T 8T 9T 10T 11T 12T
C
E
197.92 Mb 198.03 Mb 198.14 Mb 198.25 Mb
TNNT2PKP1 TNNT1
LAD1
PHLDA3
CSRP1
2
1
0
-1
-2
PHLDA3
ABL2/1q24-1q25
LAMC2/1q25-1q31
TPR/1q25
PTGS2/1q25.2-1q25.3
PTPN7/1q32
PCTK3/1q31-1q32
KISS1/1q32
RBBP5/1q32
MDA7(IL24)/1q32
PPP2R5A/1q32
ATF3/1q32
PTPN14/1q32
CENPF/1q32
TGFB2/1q41
14
2T 11T
NT
N
T
T
T
N
Figure 7. PHLDA3 Locus Is Lost and PHLDA3 Expression Is Downregulated in LCNECs
(A) Chromosomal locations of PHLDA3 gene, BACs used in CGH analysis, and microsatellite markers.
(B) Chromosome copy number alterations analyzed by MCG cancer array-800 CGH. When the signal ratio (test signal/reference signal) was less than 0.8, it was
defined as chromosomal loss. Signal ratios less than 0.8 are in shaded boxes.
(C) Representative results of Agilent 44KCGH analysis on thePHLDA3 gene locus in LCNEC samples. Chromosomal copy number ratio (tumor DNA/normal DNA)
converted to log2 data at each oligonucleotide probe was plotted (green, red, and black spots indicate lost, amplified, and retained signals, respectively). The
location of the PHLDA3 gene locus is shown by a shaded column. Small chromosomal deletions, including PHLDA3 locus, were detected in two LCNEC cases
(blue lines, derived from patients L2 and L5, see Figure S15B), while no copy number loss was observed in the other case (red line, patient L17). Chromosome
copy numbers shown by blue and red lines were calculated by applying a weighted moving-average window of 1 Mb.
(D) Expression of PHLDA3 was analyzed by quantitative RT-PCR. Total RNAs were prepared from normal lung tissues (derived from patients A–E) and LCNECs
(derived from patients 1T–12T). PHLDA3 mRNA levels were analyzed as in Figure 1D. In the right column, the mean expression ± SD of PHLDA3 expression in
normal lungs and tumor samples is shown.
(E) LCNEC tumor sections were subjected to immunohistochemistry to detect activated Akt. Stronger positive brown signals were detected in tumor regions (T)
compared to normal tissue regions (N).detected in LCNEC and carcinoid samples (11/29 LCNECs and
3/13 carcinoids showed chromosome loss at the PTPN7 locus,
Figures 7B and S15A). In addition, we analyzed another cohort
of 17 primary LCNECs withmuch higher resolution using the Agi-
lent 44K oligonucleotide array, and 5 tumor samples showed
deletion of the PHLDA3 gene locus, further demonstrating thehigh frequency of chromosome loss at the PHLDA3 locus in
LCNECs (Figures 7C and S15B). To validate chromosome copy
number alterations detected by comparative genomic hybridiza-
tion (CGH), we next determined allelic loss in that region using
microsatellite markers in 12 CGH-analyzed LCNEC samples.
Five of six samples showing chromosomal loss by CGH analysisCell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc. 547
concordantly revealed loss of heterozygosity (Figure S15C).
Moreover, 3 of 6 samples showing no chromosomal loss by
CGH analysis had allelic imbalance; therefore, collectively, 9 of
12 LCNECs had chromosomal abnormality at thePHLDA3 locus.
We also analyzed p53 and PTEN status in 32 LCNEC samples
(Figures S16A and S16B). The association between PHLDA3
loss and WT genotype of PTEN was statistically insignificant
(p = 0.68, by Fisher’s exact test). PHLDA3 and PTEN inhibit the
PI3K/Akt pathway by different mechanisms and, as shown for
MM468 cells lacking PTEN, loss of PHLDA3 is additive to
PTEN loss in Akt inhibition (Figures 4–6); therefore, it is reason-
able that PTEN loss is not mutually exclusive to PHLDA3 loss.
On the other hand, while 63% (5/8) of tumors with WT p53 ex-
hibited PHLDA3 loss, only 13% (3/24) with nonfunctional p53
had PHLDA3 loss; however, most likely due to the limited
numbers of LCNEC samples, the association of PHLDA3 loss
and WT genotype of p53 was insignificant (p = 0.088).
Reduced PHLDA3 Expression and Elevated Akt
Activation in LCNECs
We then analyzed whether such high frequency of chromosomal
loss and aberration leads to abnormal PHLDA3 expression in
tumors. As shown in Figure 7D, PHLDA3 expression was exam-
ined in 5 normal lung tissues and 11 CGH-analyzed LCNEC
samples by quantitative RT-PCR. Except for one sample, ob-
tained from a patient receiving chemotherapy prior to surgery
(3T), all samples showed significant reduction of PHLDA3
expression. Aswe found no somaticmutationwithin thePHLDA3
gene open reading frame in the 12 tumor samples described in
Figures 7B and 7C (data not shown) and the highly reduced
PHLDA3 expression in these tumors cannot be explained solely
by hemizygous chromosome loss, PHLDA3 locus in tumors
might have undergone epigenetic changes, resulting in reduced
PHLDA3 expression.
As a consequence of decreased PHLDA3 expression, we
analyzed whether Akt activation occurs in these tumors. Immu-
nohistochemistry of 32 LCNECs, including 10 tumors analyzed
for PHLDA3 expression, revealed Akt activity levels in these
tumors. Elevated phospho-Akt staining was detected in 27
tumor samples (including 9 analyzed for PHLDA3 expression),
in which phospho-Akt staining was detected on the cellular
membrane, cytoplasm, and nuclei (Figures 7E and S16). Taken
together, these results indicate that PHLDA3 may exhibit
a tumor-suppressing function in LCNECs through Akt inhibition.
DISCUSSION
PHLDA3 Is a PH Domain-Only Protein
and an Akt Repressor
We have demonstrated that the PHLDA3 gene is a direct target
gene of p53. Although PHLDA3 has been identified as a p53-
inducible gene by several groups, this report is the first to identify
PHLDA3 as a direct target gene of p53 (Jen and Cheung, 2005;
Kerley-Hamilton et al., 2005). Previously, the murine PHLDA3
(also named Tih1) gene was cloned as the closest paralog of
murine Ipl, also known as PHLDA2 (Frank et al., 1999). The Ipl
gene is expressed in the yolk sac, placenta, and fetal liver, while
PHLDA3 is expressed in multiple fetal and adult tissues,548 Cell 136, 535–550, February 6, 2009 ª2009 Elsevier Inc.indicating that these two genes have nonoverlapping functions
in development. In agreement, Ipl knockout mice showed
placental overgrowth, confirming that at least one of Ipl’s biolog-
ical functions is to regulate placental growth, while PHLDA3
knockout mice did not show this phenotype (Frank et al., 2002).
Both PHLDA3 and Ipl proteins are mostly composed of the PH
domain. PIP binding analysis was performed using PH domains
of PHLDA3 and Ipl proteins, and both bound to PIP with broad
specificity for PIP (Figure 3C and Saxena et al., 2002); however,
their physiological function remained unclear. Here, we showed
that PHLDA3 functions as a PH domain-only protein and inter-
fereswith another PHdomain-containing protein, Akt (Figure 6G).
It has been proposed that specific binding of PH domains to
PIP is necessary but not sufficient to recruit the PH domain to
the membrane, and alternative co-operative mechanisms are
required (Lemmon and Ferguson, 2000; Maffucci and Falasca,
2001). It is also suggested that binding of PH domains to other
membrane components, most probably proteins, is essential
to enable specific participation in the regulation of specific
signaling pathways (Varnai et al., 2005). In agreement, it has
been reported that among PIP3-binding PH domains, those of
Btk, Akt, and Gab1 have Akt-inhibiting ability while those of
Grp1 and ARNO do not (Ren and Wu, 2003; Varnai et al.,
2005). Although it was shown that PIP3 binding ability is required
for Akt inhibition, not all PH domains that bind PIP3 have Akt-
inhibiting activity, indicating the importance of alternative co-
operative mechanisms in selective functions of PH domains.
PHLDA3 and the isolated PH domain of Akt similarly inhibited
the Akt pathway but had almost no effect on the Grp1-regulated
pathway, showing the selective function of PHLDA3 (Figure 3).
Results by in vitro protein-lipid overlay assay demonstrated
that PHLDA3 interferes with Akt binding to PIP directly (Fig-
ure 4F); however, alternative mechanisms may cause PHLDA3
to function specifically as a dominant-negative form of Akt, and
it is an important future issue to determine whether such alterna-
tive mechanisms exist.
Functions of PHLDA3 in Lung Endocrine Tumors
By comprehensive analysis of human lung tumors using array-
based CGH analysis, we found that the PHLDA3 genomic locus
is frequently lost in LCNECs and carcinoids, both of which are
lung endocrine tumors. Lung endocrine tumors store and release
small peptides and biogenic amines and are divided into four
subtypes: (1) LCNEC, (2) carcinoid, (3) atypical carcinoid, and
(4) small-cell lung cancer (Righi et al., 2007). Although lung endo-
crine tumors have certain uniform features on microscopy and
immunohistochemical staining, they have a distinct incidence,
epidemiology, and metastatic propensity and distinct clinical
characteristics; therefore, defining their molecular and cellular
characteristics is essential to improving diagnosis and therapy.
The high incidence of loss of the PHLDA3 genomic locus may
account for a molecular characteristic of LCNECs and carci-
noids. LCNEC has aggressive clinical behavior, showing poor
prognosis and high affinity for distant metastasis (Righi et al.,
2007). In addition, LCNEC was recognized rather recently, and
therefore no efficient therapy has been established. It has been
reported that nicotine and NKK (tobacco carcinogen) bind to
nicotinic acetylcholine receptor and activate the Akt pathway
and contribute to tobacco-related carcinogenesis (West et al.,
2003). Since LCNEC is directly related to smoking, our findings
suggest that decreased expression of PHLDA3 may play an
important role in the development and malignant progression
of LCNEC. Accordingly, introducing efficient therapies for Akt
repression may lead to a better prognosis for LCNEC patients.
In summary, we present a novel Akt-inhibiting pathway, in
which Akt activity is inhibited by a PH domain-only protein,
PHLDA3. Since PHLDA3 binds to various PIP, and there are
numerous PH domain-containing proteins, further investigation
will clarify whether PHLDA3 targets proteins other than Akt.
Moreover, further detailed analysis of PHLDA3 abnormality in
human cancers and tumor formation in PHLDA3 knockout
mice is necessary to assess the involvement of PHLDA3 in
tumorigenesis.
EXPERIMENTAL PROCEDURES
For further detailed experimental procedures, please see the Supplemental
Experimental Procedures.
ChIP-chip Assay and ChIP Sequence Analysis
For p53 induction, cells were treated with 5-FU (0.375 mM for 9 hr) and UV
(10 J, harvested 9 hr post-irradiation). ChIP sequence analysis was performed
on Illumina cluster station and 1G analyzer following the manufacturer’s
instructions.
p53 Pull-Down Assay by Biotinylated DNA Probe
Biotinylated probes were attached to streptavidin-magnetic beads and incu-
bated with cell lysate prepared from p53-overexpressing H1299 cells.
Protein-Lipid Overlay Assay
Various phospholipids were spotted onto nitrocellulose membranes and
incubated with purified proteins. Protein binding to the phospholipids was
detected by enhanced chemiluminescence.
Cell Spreading and Cell Attachment Assay
Assay was performed as described (Varnai et al., 2005). COS7 cells were
transfected with the indicated constructs for 24 hr. For the cell-spreading
assay, cells were then plated on fibronection-coated chamber slides and
harvested 20 min after plating. For the attachment assay, cells were divided
into three aliquots, one of which was immediately harvested. The other two
aliquots were plated and allowed to attach for 30 min. Attached cells were
harvested and analyzed by western blotting.
Quantification of Cellular PI(3,4,5)P3
PI(3,4,5)P3 was quantified using a PIP3 mass strip kit (Echelon Biosciences
Inc., Salt Lake City, UT). Lipids were extracted from 3 3 106 MM468 cells
infected with Ad-LacZ or Ad-PHLDA3, and cells were treated with LY294002
for 12 hr.
Array-Based Comparative Genomic Hybridization Analysis
BAC CGH array hybridization was carried out as described using MCG cancer
array-800 (Peng et al., 2005). For higher-density oligonucleotide array CGH,
we used Human Genomic CGH microarray 44B (Agilent Technologies, Palo
Alto, CA).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, and 16 figures and can be found with this article online
at http://www.cell.com/supplemental/S0092-8674(08)01563-8.ACKNOWLEDGMENTS
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